Trademark: 97152382
Word
QFIDYN
Status
Registered
Status Code
700
Status Date
Tuesday, February 20, 2024
Serial Number
97152382
Registration Number
7307766
Registration Date
Tuesday, February 20, 2024
Mark Type
4000
Filing Date
Thursday, December 2, 2021
Published for Opposition
Tuesday, December 5, 2023

Trademark Owner History
CSL Behring GmbH - Original Registrant

Classifications
5 Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD

Trademark Events
Feb 20, 2024
Notice Of Registration Confirmation Emailed
Feb 20, 2024
Registered-Principal Register
Dec 5, 2023
Official Gazette Publication Confirmation E-Mailed
Dec 5, 2023
Published For Opposition
Nov 15, 2023
Notification Of Notice Of Publication E-Mailed
Oct 31, 2023
Electronic Record Review Complete
Oct 27, 2023
On Hold - Electronic Record Review Required
Oct 24, 2023
Approved For Pub - Principal Register
Aug 7, 2023
Teas/Email Correspondence Entered
Aug 7, 2023
Correspondence Received In Law Office
Aug 7, 2023
Teas Response To Office Action Received
Jun 6, 2023
Notification Of Non-Final Action E-Mailed
Jun 6, 2023
Non-Final Action E-Mailed
Jun 6, 2023
Non-Final Action Written
May 11, 2023
Teas/Email Correspondence Entered
May 11, 2023
Correspondence Received In Law Office
May 11, 2023
Assigned To Lie
Feb 8, 2023
Teas Response To Office Action Received
Sep 25, 2022
Notification Of Non-Final Action E-Mailed
Sep 25, 2022
Non-Final Action E-Mailed
Sep 25, 2022
Non-Final Action Written
Sep 12, 2022
Assigned To Examiner
Dec 6, 2021
New Application Office Supplied Data Entered
Dec 6, 2021
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24